Renalytix plc (RENX) ORD GBP0.0025
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
Renalytix surges on takeover approach
4 March 2024 11:28
(Sharecast News) - Renalytix surged on Monday after saying it had received an unsolicited takeover approach from "a large and well-capitalised publicly listed strategic diagnostics company".
-
Renalytix shares jump on draft US Medicare coverage decision
9 February 2024 10:38
(Sharecast News) - Renalytix shares were rocketing on Friday morning, after it announced that the Centers for Medicare and Medicaid Services (CMS) in the US had published a draft local coverage determination...
-
Renalytix kidney test claims allowed by US Patent Office
6 October 2023 11:35
(Sharecast News) - Diagnostic artificial intelligence (AI) specialist Renalytix announced an enhancement to its intellectual property portfolio for its KidneyIntelX.dkd test on Friday.
-
Renalytix gets KidneyIntelX included in major clinical guidelines
21 August 2023 12:39
(Sharecast News) - Renalytix announced on Monday that its signature solution 'KidneyIntelX' has secured a spot in the draft Kidney Disease Improving Global Outcomes (KDIGO) 2023 clinical practice...
-
Renalytix launches kidney disease test in Arabian Gulf countries
21 July 2023 16:11
(Sharecast News) - Renalytix announced the commercial availability of 'kidneyintelX.dkd' testing in six Gulf Cooperation Council (GCC) markets on Friday - Saudi Arabia, Bahrain, Qatar, Oman,...
-
Renalytix test gets US FDA marketing authorisation
30 June 2023 15:49
(Sharecast News) - Renalytix announced on Friday that the US Food and Drug Administration (FDA) had granted De Novo marketing authorisation for its 'KidneyIntelX.dkd' prognostic test.
-
Renalytix secures expanded coverage in Washington, DC area
22 May 2023 12:18
(Sharecast News) - Kidney disease diagnostics developer Renalytix announced the expansion of insurance coverage in the US for its flagship product KidneyIntelX on Monday.
-
Renalytix reports positive study on clinical value of KidneyIntelX
19 April 2023 13:52
(Sharecast News) - Biotechnology company Renalytix announced the publication of new case studies in the Diabetic Nephropathy journal on Wednesday, highlighting the clinical value of 'KidneyIntelX'...
-
Renalytix rises on publication of positive evidence
29 November 2022 17:14
(Sharecast News) - Renalytix announced new real-world evidence, printed in the Primary Care and Community Health publication, on Tuesday.
-
Renalytix reports positive outcomes from Mount Sinai
10 June 2022 11:48
(Sharecast News) - Renalytix updated the market on the deployment of its 'KidneyIntelX' bioprognostic testing in 1,112 adult diabetic kidney disease (DKD) patients at Mount Sinai Health System on...
-
Renalytix completes financing to support its growth
8 April 2022 15:29
(Sharecast News) - Renalytix announced the completion of a $30m (£23.06m) financing package on Friday, to support its growth and for general working capital.
-
Revenue rises, losses widen in first half at Renalytix
31 March 2022 12:44
(Sharecast News) - Artificial intelligence (AI)-focussed diagnostics company Renalytix reported first-half revenue of $1.3m (£0.99m) in its first half on Thursday, up from $0.4m year-on-year.
Company announcements Announcements
-
Issue of Shares and Rule 2.9 Announcement
22 April 2024 17:27
Renalytix (Reg S)
-
Result of General Meeting
22 April 2024 16:09
Renalytix (Reg S)
-
Form 8.5 (EPT/RI) - Renalytix plc
22 April 2024 12:00
Renalytix (Reg S)
-
Form 8.3 - Renalytix plc
18 April 2024 13:13
Renalytix (Reg S)
-
Management Change
18 April 2024 07:00
Renalytix (Reg S)
-
Form 8.3 - Renalytix plc
17 April 2024 17:17
Renalytix (Reg S)
-
Form 8.3 - Renalytix plc
17 April 2024 14:57
Renalytix (Reg S)
-
Form 8.3 - Renalytix PLC
17 April 2024 14:29
Renalytix (Reg S)
-
Form 8.3 - Renalytix plc
17 April 2024 14:27
Renalytix (Reg S)
-
Rule 2.9 Announcement
16 April 2024 13:08
Renalytix (Reg S)
-
Form 8.5 (EPT/RI) - Renalytix plc
16 April 2024 12:00
Renalytix (Reg S)
-
Form 8.3 - Renalytix plc
15 April 2024 17:58
Renalytix (Reg S)
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.